News for AnaptysBio, Inc. (0HFQ.L)

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA re

**media[552860]**

**media[552854]**

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Aadi Bioscience Inc. On December 31,

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's s...

AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, Wednesday announced positive data from Phase 2b RENOIR study of rosnilimab for the treatment of rheumatoid arthritis (RA).

Virginia-based Spire Global, Inc. (SPIR) is down over 52 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statist

**media[538162]**

PR NewswireWASHINGTON and SAN DIEGO, Feb. 3, 2025 Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday. Shares of Progress Software Corporation PRGS fell sh...

Shares of Netflix, Inc. NFLX rose sharply in today's pre-market trading as the company reported stronger-than-expected fourth-quarter financial results. Netfli...

On January 15, 2025, EcoR1 Capital, LLC (Trades, Portfolio) executed a significant transaction involving Zymeworks Inc. The firm added 167,654 shares of Zymewor

On January 10, 2025, EcoR1 Capital, LLC (Trades, Portfolio) executed a notable transaction involving Zymeworks Inc, a clinical-stage biopharmaceutical company.

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. ( ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ther

On January 2, 2025, EcoR1 Capital, LLC (Trades, Portfolio) executed a significant transaction involving AnaptysBio Inc (ANAB). The firm added 85,098 shares to i